China vs Peru: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
China
0.1%
in 2024
Peru
0.1%
in 2024
China rank
112th
Peru rank
112th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- China
- Peru
How they compare
China currently reports 0.1% against 0.1% in Peru, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was China ahead.
China ranks 112th and Peru ranks 112th of 215 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.1% | 0.1% | China |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, China or Peru?
- China, at 0.1% against 0.1% in Peru as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between China and Peru?
- 0.0%, with China ahead.
- How many years of comparable data are there for China and Peru?
- 10 years are reported by both, from 2015 to 2024.
- How do China and Peru rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- China ranks 112th and Peru ranks 112th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.